

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
BGB-24714 (SMAC Mimetic) +/- Chemotherapy				Advanced solid tumors
BGB-3245 (BRAF inhibitor)				Advanced solid tumors with BRAF mutations
BGB-26808 (HPK1 inhibitor) +/- Tislelizumab (anti-PD-1)				Advanced solid tumors
BGB-30813 (DGKζ inhibitor) +/- Tislelizumab				Advanced or metastatic solid tumors
BGB-A3055 (anti-CCR8) +/- Tislelizumab				Select advanced or metastatic solid tumors
BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab				Advanced solid tumors
BGB-B167 +/- Tislelizumab				Advanced or metastatic solid tumors
BGB-A445 (anti-OX40) +/- Tislelizumab				Select advanced solid tumors
Tislelizumab + BGB-A445				Advanced solid tumors
BGB-A445 +/- Tislelizumab +/- Sitravatinib (multikinase inhibitor) +/- BGB-15025 (HPK1 inhibitor) +/- Chemotherapy				NSCLC after anti-PD-(L)1 therapy
LBL-007 (anti-LAG-3) +/- Tislelizumab + Bevacizumab + Capecitabine*				Maintenance in unresectable or metastatic MSS/mismatch repair proficient CRC
LBL-007 + Tislelizumab + Chemotherapy*				1L unresectable locally advanced or metastatic ESCC
Lifirafenib (RAF inhibitor) + Mirdametinib (MEK inhibitor)†				Advanced solid tumors
Ociperlimab (anti-TIGIT) + Tislelizumab				1L PD-L1 high advanced NSCLC
				2L PD-L1+ advanced ESCC
				2L+ cervical cancer
				Advanced solid tumors
Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)				1L HCC
Ociperlimab + Tislelizumab + Chemotherapy				1L NSCLC
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy				Previously untreated, stage III unresectable NSCLC
Pamiparib (PARP 1/2 inhibitor)				2L/3L maintenance platinum-sensitive OC
Tislelizumab				1L HCC
				2L/3L NSCLC
				Neoadjuvant MSI-high or dMMR CRC
				Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab +/- Surzebiclimab (anti-TIM-3) +/- LBL-007*				Advanced solid tumors

\*In collaboration with Nanjing Leads Biolabs.  
 †In collaboration with SpringWorks Therapeutics.

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BRAF, B-Raf proto-oncogene; CEA, carcinoembryonic antigen; CCR8, C-C chemokine receptor 8; CRC, colorectal cancer; DGKζ, diacylglycerol kinase zeta, and HNSCC; dMMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HPK1, hematopoietic progenitor kinase 1; LAG-3, lymphocyte-activation gene 3; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PD-L1, programmed death-ligand 1; PIK3δ, phosphoinositide 3-kinase delta; SMAC, Second Mitochondrial-derived Activator of Caspases; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T cell immunoglobulin and mucin domain-containing protein 3; VEGF, vascular endothelial growth factor.

Australia, New Zealand	China	Australia, US
Australia	Worldwide	

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab +/- Surzebiclimab +/- LBL-007*				1L recurrent or metastatic HNSCC
Tislelizumab +/- Ociperlimab +/- LBL-007*				Resectable stage II/IIIA NSCLC
Tislelizumab +/- BGB-A445 +/- LBL-007 +/- Chemotherapy*				1L advanced, unresectable, or metastatic NSCLC
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)				Advanced solid tumors
Tislelizumab + BGB-15025 (HPK1 inhibitor)				Advanced solid tumors
Tislelizumab + Chemoradiotherapy				Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy				Resectable ESCC
Tislelizumab + Chemotherapy				1L advanced ESCC
				1L GC/GEJC
				Resectable stage II or IIIA NSCLC
				1L advanced nasopharyngeal cancer
				1L advanced UBC
				1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy†				1L/2L GC/GEJC
Tislelizumab + Fruquintinib (VEGFR inhibitor)‡				Advanced GC/GEJC, CRC, and NSCLC
				Advanced triple negative BC, EC, and CRC
Tislelizumab + Lenvatinib (VEGFR kinase inhibitor)				1L HCC
				Advanced solid tumors
Tislelizumab + Sitravatinib (multikinase inhibitor)				Advanced NSCLC after anti-PD-(L)1 therapy
				Advanced ESCC after anti-PD-(L)1 therapy
Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)‡				Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)§				2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab§				1L HER2+ BC and 1L HER2+ GC/GEJC
				1L HER2+ advanced/metastatic GC/EC

\*In collaboration with Nanjing Leads Biolabs.  
†In collaboration with Leap Therapeutics, Inc.  
‡Clinical collaboration with Hutchison Medipharma International.  
§In collaboration with Zymeworks, Inc.

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BTC, biliary tract cancer; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; EC, endometrial cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor-2; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; UBC, urothelial bladder cancer; VEGFR, vascular endothelial growth factor receptors.

Australia, China, US	China	Australia, China	China, Thailand
United States	Worldwide	China, S. Korea	